Table 1.

Baseline demographics and clinical characteristics

Characteristic	Total (N=61)
Median age (range), years	62 (44–84)
≥65 years, no. (%)	27 (44)
≥70 years, no. (%)	15 (25)
Diagnosis, no. (%)
Chronic lymphocytic leukemia	61 (100)
Performance status, no. (%)
0	22 (36)
1	36 (59)
2	3 (5)
Bulky lymph node disease, no. (%)
≥5 cm in diameter	28 (46)
≥10 cm in diameter	3 (5)
Rai risk classification,* no. (%)
Low	1 (2)
Intermediate	19 (31)
High	41 (67)
Median (range) no. of prior therapies	3 (1–13)
Cytopenia at baseline, no. (%)
Absolute neutrophil count ≤1,500 μL	15 (25)
Hemoglobin ≤11.0 g/dL	21 (34)
Platelets ≤100,000/μL	32 (53)
Prognostic factors, no. (%)
Unmutated immunoglobulin variable-region heavy-chain gene	38/51 (75)
(17)(p13.1) deletion†	18/59 (31)
(11)(q22.3) deletion†	17/59 (29)
β2-microglobulin >3.5 mg/L	47/58 (81)

^*Rai stage is derived at time of screening for this trial.

^†Determined by local laboratory or medical history.